Journal of Gastroenterology

, Volume 53, Issue 6, pp 718–724 | Cite as

Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children

  • Chika Kusano
  • Takuji Gotoda
  • Sho Suzuki
  • Hisatomo Ikehara
  • Mitsuhiko Moriyama
Original Article—Alimentary Tract



Helicobacter pylori infection is a risk factor for gastric cancer, and it has been reported that eradication of H. pylori is effective for preventing such cancer. Recently, H. pylori eradication has been performed in children as first-line therapy against gastric cancer. Here, we report use of triple therapy with a potassium-competitive acid blocker (P-CAB) for H. pylori eradication in children.


H. pylori infection testing and eradication therapy began in fiscal year 2015 in junior high school students located in Yurihonjo city and Nikaho city, Akita prefecture, Japan. Urine-based immunochromatography, stool antigen enzyme-linked immunosorbent assay tests, and serum antibody tests were performed as the initial screening examination. Those who tested positive on one of the three examinations then underwent a urea breath test (13C-UBT). Those who tested positive on 13C-UBT and expressed the desire to undergo H. pylori eradication then received eradication therapy comprising 20 mg P-CAB, 750 mg amoxicillin, and 200 mg clarithromycin twice a day for 7 days. At least 8 weeks after treatment, eradication success was evaluated using 13C-UBT.


A total of 118 students received eradication therapy. Eradication rates were 81.3% (95% confidence interval: 74.3–88.4, 96/118) in ITT analysis and 85.7% (95% confidence interval: 79.1–92.9 96/112) in PP analysis. Adverse effects associated with eradication therapy were observed in 25 of 118 subjects (21.1%), seven of whom required hospital treatment (rash in five, vomiting in two). All seven subjects either discontinued therapy or were administered anti-allergy drugs, which resulted in swift alleviation of symptoms.


First-line triple therapy with a P-CAB for H. pylori eradication in children was found to be safe.


Children Helicobacter pylori Potassium-competitive acid blocker 



The authors acknowledge the considerable support of the public health nurses and all employees of the local governments of Yurihonjo city and Nikaho city, as well as the medical staff and assistants of Yuri Kumiai General Hospital, Akita, Japan.

Author contributions

Guarantor of the article: CK. Conceptualization, data analysis, and manuscript preparation: CK, TG and SS. Data collection: CK, HI, SS. Critical review of the manuscript: TG and MM. All authors have read and approved the submitted version of this manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Financial support

This project was supported by the anticancer fund of Yurihonjo city and Nikaho city.


  1. 1.
    Nomura A, Stemmermann GN, Chyou PH, et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325:1132–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Kikuchi S, Wada O, Nakajima T, et al. Serum anti-Helicobacter pylori antibody and gastric carcinoma among young adults. Research group on prevention of gastric carcinoma among young adults. Cancer. 1995;75:2789–93.CrossRefPubMedGoogle Scholar
  3. 3.
    Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Eslick GD, Lim LL, Byles JE, et al. Association of Helicobacter pylori infection with gastric carcinoma. Am J Gastroenterol. 1999;94:2373–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Palli D, Masala G, Del Giudice G, et al. CagA+ Helicobacter pylori infection and gastric cancer risk in EPIC-EURGAST study. Int J Cancer. 2007;120:859–67.CrossRefPubMedGoogle Scholar
  6. 6.
    Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open level, randomized controlled trial. Lancet. 2008;372:392–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high risk region of China: a randomized controlled trial. JAMA. 2004;291:187–94.CrossRefPubMedGoogle Scholar
  8. 8.
    Akamatsu T, Ishikawa S, Okudaira S, et al. Introduction of an examination and treatment for Helicobacter pylori infection in high school health screening. J Gastroenterol. 2011;46:1353–60.CrossRefPubMedGoogle Scholar
  9. 9.
    Koletzko S, Jones NL, Goodman KJ, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011;53:230–43.PubMedGoogle Scholar
  10. 10.
    Gottrand F, Kalach N, Spyckerelle C, et al. Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: a prospective randomized double-blind trial. J Pediatr. 2001;139:664–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Ri Francavilla, Lionetti E, Castellaneta SP, et al. Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology. 2005;129:1414–9.CrossRefGoogle Scholar
  12. 12.
    Gi Oderda, Shcherbakov P, Bontems P, et al. Results from the pediatric European register for treatment of Helicobacter pylori (PERTH). Helicobacter. 2007;12:150–6.CrossRefGoogle Scholar
  13. 13.
    Koletzko S, Richy F, Bontems P, et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut. 2007;12:1711–6.Google Scholar
  14. 14.
    Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther. 2005;108:294–307.CrossRefPubMedGoogle Scholar
  15. 15.
    Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335:231–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase,1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339:412–20.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hori Y, Matsukawa J, Takeuchi T, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther. 2011;337:797–804.CrossRefPubMedGoogle Scholar
  18. 18.
    Kusano C, Gotoda T, Ishikawa H, et al. The administrative project of Helicobacter pylori infection screening among junior high school students in an area of Japan with a high incidence of gastric cancer. Gastric Cancer. 2017;20:6–9.CrossRefGoogle Scholar
  19. 19.
    Rowland M, Lambert I, Gormally S, et al. Carbon 13-labeled urea breath test for the diagnosis of Helicobacter pylori infection in children. J Pediatr. 1997;131:815–20.CrossRefPubMedGoogle Scholar
  20. 20.
    Bazzoli F, Cecchini L, Corvaglia L, et al. Validation of the 13C-urea breath test for the diagnosis of Helicobacter pylori infection in children: a multicenter study. Am J Gastroenterol. 2000;95:646–50.CrossRefPubMedGoogle Scholar
  21. 21.
  22. 22.
  23. 23.
    MCNicholl AG, Linares PM, Nyssen OP, et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36:414–25.CrossRefPubMedGoogle Scholar
  24. 24.
    Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009;2:295–314.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Matsukawa J, Hori Y, Nishida H, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011;81:1145–51.CrossRefPubMedGoogle Scholar
  26. 26.
    Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65:1439–46.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Suzuki S, Gotoda T, Kusano C, et al. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy. Am J Gastroenterol. 2016;7:949–56.CrossRefGoogle Scholar
  28. 28.
    Shichijo S, Hirata Y, Niikura R, et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: a multicenter retrospective study in clinical practice. J Dig Dis. 2016;10:670–5.CrossRefGoogle Scholar
  29. 29.
    Tsujimae M, Yamashita H, Hashimura H, et al. A comparative study of a new class of gastric acid suppressant agent named vonoparazan versus esomeprazole for the eradication of Helicobacter pylori. Digestion. 2016;94:240–6.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46:106–14.CrossRefPubMedGoogle Scholar
  31. 31.
    Okuda M, Kikuchi S, Mabe K, et al. Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan. Pediatr Int. 2017;59:57–61.CrossRefPubMedGoogle Scholar
  32. 32.
    Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010;15:1–20.CrossRefPubMedGoogle Scholar
  33. 33.
    Kato S, Fujimura S. Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years. Pediatr Int. 2010;52:187–90.CrossRefPubMedGoogle Scholar
  34. 34.
    Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65:870–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Graham DY. Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues. Gut. 2017;66:384–6.PubMedGoogle Scholar
  36. 36.
    Ebo DG, Leysen J, Mayorga C, et al. The in vitro diagnosis of drug allergy: status and perspectives. Allergy. 2011;66:1275–86.CrossRefPubMedGoogle Scholar
  37. 37.
    Kamiya K, Nishio E, Tokura Y. Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. J Dermatol. 2015;43:340–1.CrossRefPubMedGoogle Scholar
  38. 38.
    Riemer AB, Gruber S, Pali-scholl I, et al. Suppression of gastric acid increases the risk of developing immunoglobulin E-mediated drug hypersensitivity: human diclofenac sensitization and a murine sensitization model. Clin Exp Allergy. 2010;40:486–93.CrossRefPubMedGoogle Scholar
  39. 39.
    Brunner R, Wallmann J, Szalai K, et al. Aluminium per se and in the anti-acid drug sucralfate promotes sensitization via the oral route. Allergy. 2009;64:890–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Pickard C, Sampson AP. Does gastric acid suppression increase the risk of drug allergies? Alin Ecp Allergy. 2010;40:362–4.Google Scholar
  41. 41.
    Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Dooley CP, Cohen H, Fitzgibbons PL. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med. 1989;321:1562–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Correa P. Human gastric carcinogenesis: a multi-step and multi-factorial process. First American Cancer Society Award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52:6735–40.PubMedGoogle Scholar
  44. 44.
    Yanaoka K, Oka M, Ohata H, et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer. 2009;125:2697–703.CrossRefPubMedGoogle Scholar
  45. 45.
    Okuda M, Osaki T, Lin Y, et al. Low prevalence and incidence of Helicobacter pylori infection in children: a population-based study in Japan. Helicobacter. 2015;20:133–8.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2017

Authors and Affiliations

  • Chika Kusano
    • 1
    • 2
  • Takuji Gotoda
    • 1
  • Sho Suzuki
    • 1
    • 2
  • Hisatomo Ikehara
    • 1
    • 2
  • Mitsuhiko Moriyama
    • 1
  1. 1.Division of Gastroenterology and Hepatology, Department of MedicineNihon University School of MedicineTokyoJapan
  2. 2.Division of GastroenterologyYuri Kumiai General HospitalAkitaJapan

Personalised recommendations